Does Rallies show 13F holders for BCAX?

Yes. Rallies tracks hedge fund and 13F ownership data for BCAX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BCAX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BCAX. It does not provide personalized investment advice.

BCAX (Bicara Therapeutics Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Bicara Therapeutics Inc. Common Stock (BCAX) is a publicly traded Healthcare sector company. As of May 21, 2026, BCAX trades at $20.43 with a market cap of $1.27B and a P/E ratio of -8.10. BCAX moved +2.05% today. Year to date, BCAX is +26.82%; over the trailing twelve months it is +35.84%. Its 52-week range spans $7.80 to $28.09. Analyst consensus is strong buy with an average price target of $30.99. Rallies surfaces BCAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BCAX stock?

Hedge funds tracked by Rallies that own BCAX include Orbimed Advisors and Soros Fund. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Bicara Therapeutics Inc. Common Stock.

BCAX Key Metrics

Key financial metrics for BCAX
Metric	Value
Price	$20.43
Market Cap	$1.27B
P/E Ratio	-8.10
EPS	$-2.52
Dividend Yield	0.00%
52-Week High	$28.09
52-Week Low	$7.80
Volume	4.42K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-137.95M
Gross Margin	0.00%

Top Hedge Funds Holding BCAX

Orbimed Advisors holds 667.30K shares of BCAX, changed +219.13% as of Mar 31, 2026.
Soros Fund holds 20.00K shares of BCAX, changed +0.00% as of Sep 30, 2024.

Latest BCAX News

Bicara posts $8.3M Q1 net loss, advances BT-11 Phase 1b/2a and BT-12 IND — May 12, 2026
Bicara Secures $161.8M, Holds $539.8M Cash, Q3 Ficerafusp Combo Trial — May 11, 2026
Bicara Therapeutics Launches Phase 3 FORTIFI-HN01 Trial and Raises $161.8M — Mar 30, 2026
Bicara’s Ficera Achieves 54% ORR, BofA Initiates Buy with $35 — Mar 25, 2026
Bicara Sets FORTIFY Trial at 1,500 mg Weekly Dose Versus Pembrolizumab, Mid-2027 Readout Target — Mar 6, 2026

Recent BCAX Insider Trades

Cohlhepp Ryan sold 8.00K (~$162.34K) on May 15, 2026.
Cohlhepp Ryan sold 4.50K (~$91.31K) on May 15, 2026.
Raben David sold 5.50K (~$125.83K) on Apr 27, 2026.

BCAX Analyst Consensus

11 analysts cover BCAX: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.99.

Common questions about BCAX

Who owns BCAX stock?: Hedge funds tracked by Rallies that own BCAX include Orbimed Advisors and Soros Fund. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Bicara Therapeutics Inc. Common Stock.
Does Rallies show 13F holders for BCAX?: Yes. Rallies tracks hedge fund and 13F ownership data for BCAX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BCAX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BCAX. It does not provide personalized investment advice.